Evaluate the Efficacy and Safety of Brightening Micro-needle Patch on Facial Solar Lentigines

Method: 35 subjects, Fitzpatrick Skin Type II to IV. Each subject has at least two brown solar lentigines on the face, and the two spots are independent, each with a clear boundary and diameter ≥ 0.5 cm.

This trial includes 1 screening visit (Day -1), wash-out period (2 weeks before the trial), trial period (4 weeks in total), and 3 return visits for detecting (baseline detecting at the end of the wash-out period, the 2nd week and the 4th week of the trial period).

Inclusion criteria

• Men or women between 30 and 65 years old (inclusive);
• The PI determines the subject's skin type as Fitzpatrick Skin Type II to IV;
• The PI's diagnosis is that the subject has at least two brown solar lentigines on the face, and the two spots are independent, each with a clear boundary and diameter ≥ 0.5 cm;
• The subject can understand and follow the requirements, instructions and restriction of the plan;
• The subject signs patient consent form in writing.

Exclusion criteria

• The PI's diagnosis is that the subject has tissue mutation, inflammation or other lesions on the face;
• Those who have received aggressive facial treatments within the past six months, including laser, IPL, RF (radio frequency), HIFU(high-intensity focus ultrasound), or dermal filler injection;
• Those with a history of chronic skin diseases or autoimmune diseases, such as atopic dermatitis, psoriasis, chronic urticaria, vitiligo, rosacea, keloid and so forth;
• Those who have a history of allergies to the product ingredients of the brightening micro-needle patch, the moisturizer or the sunscreen provided by the trial;
• Pregnant or lactating women;
• Those who have used facial blemish-lightening products (such as products claiming to have whitening or blemish-lightening effects), topical or oral whitening drugs within 21 days before entering the trial;
• Those who have smoking habits within 12 months before entering the trial;
• Those who have used any skin medication on the face within 30 days before entering the trial, determined by the PI to have effect on this study;
• Those who have participated in other clinical trials within 30 days before entering the trial;
• Those who are currently undergoing medical treatment and their ability to participate in this trial will be affected;
• Those who the PI considers to be unsuitable to join this trial.